Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index
December 11 2017 - 03:02PM
Business Wire
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP)
announced today that it has been selected for addition to the
NASDAQ Biotechnology Index® (Nasdaq:^NBI), which will become
effective prior to market open on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of NASDAQ-listed securities that are
classified as either biotechnology or pharmaceutical according to
the Industry Classification Benchmark. The NASDAQ Biotechnology
Index is re-ranked annually. The NASDAQ Biotechnology Index is the
basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB),
which seeks investment results that correspond generally to the
price and yield performance, before fees and expenses, of the
NASDAQ Biotechnology Index. In addition, options based on the
iShares NASDAQ Biotechnology Index Fund trade on various exchanges.
For more information about the NASDAQ Biotechnology Index please
visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
Additionally, Aurinia was recently added to the MSCI Global
Small Cap Indexes, which went into effect at close of November 30,
2017. Canada added 17 securities and deleted 7 securities from MSCI
Global Small Cap indexes.
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing voclosporin, an investigational drug, for
the treatment of LN, FSGS, MCD and DES. The company is
headquartered in Victoria, BC and focuses its development efforts
globally. For further information, see our website at
www.auriniapharma.com.
We seek safe harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171211006070/en/
Aurinia Pharmaceuticals Inc.Investor Contact:Celia
EconomidesVP, Corporate & Public
AffairsIR@auriniapharma.comorMedia:Christopher Hippolyte,
212-364-0458Christopher.hippolyte@inventivhealth.com